welcome to Treatment strategy of Chinese thrombosis disease!

Home > News > Latest Research

Cardiac stroke is early with rivaroxaban or does not increase the risk of bloody conversion


Early use of anticoagulants after cardiogenic stroke may lead to potential bleeding changes, so there is still controversy over the early use of anticoagulants. A Canadian study showed that early use of rivaroxaban after cardiogenic stroke may not increase the risk of hemorrhagic conversion. (Stroke, May 24th online) study of 60 patients with atrial fibrillation in patients with transient ischemic attack (TIA) or ischemic stroke within 14 days after receiving rivaroxaban treatment. All patients underwent MRI at 24 h and 7 days after treatment with rivaroxaban. In the MRI follow-up found that no patients with symptomatic hemorrhagic transformation. New asymptomatic hemorrhagic transformation 1 had 3 patients, asymptomatic hemorrhagic transformation 1 progressed to hemorrhagic transformation 2 had 5 patients; other patients within 7 days, hemorrhagic transformation did not change. The study concluded that mild to moderate cardiac stroke / TIA patients, early (≤ 14 d) treatment with rivaroxaban was safe. MRI showed that rivaroxaban did not increase the risk of symptomatic bleeding. (Wu Dongqiu)

Return List